For adults with moderate to severe Crohn’s disease.

#1 prescribed biologic for Crohn's and ulcerative colitis combined.

Quarterly analysis of claims data from January 2023–December 2025.

Discover the only gut-focused treatment* for Crohn’s

that works right where U need it

*ENTYVIO helps block certain inflammation-causing cells from entering the gut.

Focus U Want

Helps block inflammation right where it occurs: In your gut

*ENTYVIO helps block certain inflammation-causing cells from entering the gut.

Results U Need

Lasting relief and steroid-free remission for Crohn’s disease after 1 year


Some people with Crohn’s experienced rapid symptom relief as early as 6 weeks

Individual results may vary.

Many patients taking ENTYVIO IV achieved remission at Week 52, some without steroids. Some achieved visible improvement of the gut lining and remission at Week 6. Remission is a measure to determine when a patient with Crohn’s or UC is experiencing few to no symptoms and an improvement in their condition.

Experience U Expect

More than 10 years of patient experience


2 options for Crohn’s therapy: ENTYVIO IV infusion and the ENTYVIO Pen

ENTYVIO IV was FDA approved in May 2014.
After at least 2 IV starter doses.

ENTYVIO vial and ENTYVIO Pen.

Support U Deserve

Eligible Crohn’s ENTYVIO patients may pay as little as $0 per dose


Growing coverage for the ENTYVIO Pen§


1-on-1 support through 
EntyvioConnect for people prescribed ENTYVIO

§Coverage of the ENTYVIO Pen as of January 2025.

IV=intravenous.

Stay in the know

Sign up for ENTYVIO emails to get news and updates right to your inbox.

Discover ENTYVIO for Crohn's Disease

ENTYVIO (vedolizumab) is a biologic used to treat moderate to severe Crohn’s disease.​

You can explore more about ENTYVIO for Crohn’s—see treatment results, hear from patients with Crohn’s, and learn about support and financial help available to you.